LabGenomics Co. Ltd
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.
LabGenomics Co. Ltd (084650) - Net Assets
Latest net assets as of September 2025: ₩188.67 Billion KRW
Based on the latest financial reports, LabGenomics Co. Ltd (084650) has net assets worth ₩188.67 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩264.67 Billion) and total liabilities (₩76.00 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩188.67 Billion |
| % of Total Assets | 71.29% |
| Annual Growth Rate | 26.12% |
| 5-Year Change | 165.28% |
| 10-Year Change | 876.58% |
| Growth Volatility | 52.99 |
LabGenomics Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how LabGenomics Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LabGenomics Co. Ltd (2014–2024)
The table below shows the annual net assets of LabGenomics Co. Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩216.31 Billion | -5.18% |
| 2023-12-31 | ₩228.14 Billion | +8.99% |
| 2022-12-31 | ₩209.33 Billion | +32.73% |
| 2021-12-31 | ₩157.72 Billion | +93.41% |
| 2020-12-31 | ₩81.54 Billion | +168.08% |
| 2019-12-31 | ₩30.42 Billion | +1.05% |
| 2018-12-31 | ₩30.10 Billion | +34.70% |
| 2017-12-31 | ₩22.35 Billion | -10.75% |
| 2016-12-31 | ₩25.04 Billion | +13.04% |
| 2015-12-31 | ₩22.15 Billion | +4.31% |
| 2014-12-31 | ₩21.24 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to LabGenomics Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1667.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩146.62 Billion | 67.78% |
| Common Stock | ₩37.18 Billion | 17.19% |
| Other Components | ₩32.52 Billion | 15.03% |
| Total Equity | ₩216.31 Billion | 100.00% |
LabGenomics Co. Ltd Competitors by Market Cap
The table below lists competitors of LabGenomics Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing JIAYU Door Window Curtain
SHE:300117
|
$25.72 Million |
|
HNO International Inc
PINK:HNOI
|
$25.72 Million |
|
Grand River Commerce Inc
OTCQX:GNRV
|
$25.72 Million |
|
Iofina plc
PINK:IOFNF
|
$25.73 Million |
|
Hiroca Holdings Ltd
TW:1338
|
$25.70 Million |
|
New Delhi Television Limited
NSE:NDTV
|
$25.69 Million |
|
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
|
$25.69 Million |
|
TJ media Co. Ltd
KQ:032540
|
$25.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LabGenomics Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 227,795,426,120 to 216,314,157,970, a change of -11,481,268,150 (-5.0%).
- Net loss of 23,795,979,490 reduced equity.
- Other factors increased equity by 12,314,711,340.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-23.80 Billion | -11.0% |
| Other Changes | ₩12.31 Billion | +5.69% |
| Total Change | ₩- | -5.04% |
Book Value vs Market Value Analysis
This analysis compares LabGenomics Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.48x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.41x to 0.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩981.11 | ₩1386.00 | x |
| 2017-12-31 | ₩866.00 | ₩1386.00 | x |
| 2018-12-31 | ₩1105.46 | ₩1386.00 | x |
| 2019-12-31 | ₩986.05 | ₩1386.00 | x |
| 2020-12-31 | ₩2400.68 | ₩1386.00 | x |
| 2021-12-31 | ₩2366.37 | ₩1386.00 | x |
| 2022-12-31 | ₩3079.15 | ₩1386.00 | x |
| 2023-12-31 | ₩3068.37 | ₩1386.00 | x |
| 2024-12-31 | ₩2913.71 | ₩1386.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LabGenomics Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27.70%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.37x
- Recent ROE (-11.00%) is below the historical average (10.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 11.40% | 10.43% | 0.75x | 1.46x | ₩296.54 Million |
| 2015 | 7.34% | 6.89% | 0.74x | 1.43x | ₩-588.63 Million |
| 2016 | 2.89% | 3.01% | 0.56x | 1.73x | ₩-1.78 Billion |
| 2017 | -15.38% | -13.85% | 0.62x | 1.78x | ₩-5.67 Billion |
| 2018 | -13.20% | -14.43% | 0.58x | 1.56x | ₩-6.98 Billion |
| 2019 | 3.16% | 2.90% | 0.67x | 1.63x | ₩-2.08 Billion |
| 2020 | 52.45% | 35.79% | 1.09x | 1.34x | ₩34.61 Billion |
| 2021 | 53.17% | 41.43% | 0.99x | 1.30x | ₩68.08 Billion |
| 2022 | 23.12% | 33.43% | 0.58x | 1.20x | ₩27.46 Billion |
| 2023 | -2.05% | -6.58% | 0.23x | 1.38x | ₩-27.45 Billion |
| 2024 | -11.00% | -27.70% | 0.29x | 1.37x | ₩-45.43 Billion |
Industry Comparison
This section compares LabGenomics Co. Ltd's net assets metrics with peer companies in the Healthcare Providers & Services industry.
No peer company data available for comparison.